Tissue Drug Levels of HIV Medications

University of Minnesota22 enrolled

Overview

The aim of this study is to find out why HIV continues to make copies in people taking HIV drugs. The investigators want to know if the medications most people use to treat HIV get into the lymphatic tissue where HIV persists.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Human Immunodeficiency Virus

Interventions

Initiation of anti-retroviral therapyDRUG

Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV+ * Treatment naive or \>30 days off ARV therapy * Documented sensitivity to prescribed antiretrovirals * Age ≥ 18 years * Negative pregnancy test for eligible women of childbearing potential * Ready to start ARV therapy Exclusion Criteria: * Contraindications to surgical \& endoscopy procedures (as judged by PI) * Psychiatric or psychological illness that would make adherence to protocol procedures unlikely * Pregnancy

Locations (1)

University of Minnesota

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Intracellular antiretroviral drug concentrations

Time frame: Measured at baseline, 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months & 6 months

Secondary Outcomes

Evidence of HIV replication in blood and lymphoid tissue

Time frame: Measured at baseline, 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, & 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.